In this issue:
Vitamin D, smoking, EBV, and long-term cognitive performance in MS
Pregnancy-related MS relapses and breastfeeding
Adverse events related to biologicals for MS
Long-term safety and effectiveness of natalizumab
Cancer risk for fingolimod, natalizumab, and rituximab in MS
Modelling the impact of MS on life expectancy, QALYs and total lifetime costs
Diagnostic predictive value of the CVS for MS
Factors associated with delays in the MS diagnostic process
Higher EBV response is associated with more severe gray matter and lesion pathology in RRMS
Please login below to download this issue (PDF)